Afimkibart for moderate to severe ulcerative colitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study tests a new medicine called afimkibart for people with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if it can help control symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ulcerative colitis.
- Your ulcerative colitis is moderate to severe as determined by your doctor.
- You weigh at least 40 kg (about 88 pounds).
- You have tried at least one other ulcerative colitis treatment that did not work well enough or caused side effects.
- You are up to date with colon cancer screening as recommended by your doctor.
- If you could become pregnant, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
This is a follow-up study for people who already completed a previous trial testing afimkibart (an experimental drug) for rheumatoid arthritis. It checks whether the drug continues to work safely and effectively over a longer period.
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.